

# Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/T288858333CEN.html>

Date: May 2020

Pages: 672

Price: US\$ 2,500.00 (Single User License)

ID: T288858333CEN

## Abstracts

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes – Pipeline Review, H1 2020, provides an overview of the Type 1 Diabetes (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 6, 2, 10, 34, 28, 1, 116, 23 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 2, 1, 1, 31 and 4 molecules, respectively.

Type 1 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Type 1 Diabetes

(Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Type 1 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Metabolic Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Type 1 Diabetes (Juvenile Diabetes) - Overview

Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Development

Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment

Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics

Development

Type 1 Diabetes (Juvenile Diabetes) - Drug Profiles

Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects

Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products

Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Adocia SAS, H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Aerami Therapeutics, H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Ahead Therapeutics SL, H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Akston Biosciences Corp, H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Algiax Pharmaceuticals GmbH, H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Altheia Science SRL, H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Pipeline by ALTuCELL, H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Pipeline by Amarna Therapeutics BV, H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..1), H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..2), H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..3), H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..4), H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..5), H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..6), H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..7), H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..8), H1 2020

Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..9), H1 2020  
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..10), H1 2020  
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..11), H1 2020  
Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, H1 2020 (Contd..12), H1 2020  
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H1 2020  
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H1 2020 (Contd..1), H1  
2020  
Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, H1 2020 (Contd..2), H1  
2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

Adocia SAS

Aerami Therapeutics

Ahead Therapeutics SL

Akston Biosciences Corp

Algiax Pharmaceuticals GmbH

Altheia Science SRL

ALTuCELL

Amarna Therapeutics BV

AmideBio LLC

Anokion SA

Aphios Corp

Apodemus AB

APT Therapeutics Inc

Aptamer Sciences Inc

Arecor Ltd

Ariddad Therapeutics SL

Artery Therapeutics Inc

AstraZeneca Plc

Atlantic Bio Sci LLC

AVM Biotechnology LLC



Avotres Inc  
Axxam SpA  
Beijing Advaccine Biotechnology Company Ltd  
Beta-Cell NV  
Biocon Ltd  
BioLingus AG  
Bioorg3.14 LLC  
Biozeus Pharmaceutical SA  
BirchBioMed Inc  
Bol Pharma  
Boston Therapeutics Inc  
Bristol-Myers Squibb Co  
BTB Pharma AB  
Cancer Prevention Pharmaceuticals Inc  
CAR-T (Shanghai) Biotechnology Co Ltd  
Carlina Technologies SAS  
CellTrans Inc  
Chongqing Chenan BioPharm Co Ltd  
Compugen Ltd  
Cour Pharmaceuticals Development Co Inc  
CRISPR Therapeutics AG  
Curyx Bio Inc  
Cyteir Therapeutics Inc  
Daewoong Pharmaceutical Co Ltd  
Dendright Pty Ltd  
Diabetology (Products) Ltd  
Diamyd Medical AB  
Diasome Pharmaceuticals Inc  
DiaVacs Inc  
Dompe Farmaceutici SpA  
Dualogics Corp  
Eli Lilly and Co  
Emerald Organic Products Inc  
Endsulin LLC  
Ensol Biosciences Inc  
Enthera Srl  
EpiVax Inc  
Evotec SE  
Fairbanks Pharmaceuticals Inc

FasCure Therapeutics LLC  
Follicum AB  
Gan & Lee Pharmaceutical Ltd  
Generex Biotechnology Corp  
GeNeuro SA  
Genprex Inc  
Geropharm  
Gubra ApS  
Hanmi Pharmaceuticals Co Ltd  
Housey Pharmaceutical Research Laboratories LLC  
Iltoo Pharma  
ImCyse SA  
ImmunoMolecular Therapeutics LLC  
ImmusanT Inc  
Innovimmune Biotherapeutics Inc  
Inversago Pharma Inc  
Islexa Ltd  
Jiangsu Hengrui Medicine Co Ltd  
JN Biosciences LLC  
Johnson & Johnson  
Jortan Pharmaceuticals Inc  
Kadimastem Ltd  
Kamada Ltd  
Kiniksa Pharmaceuticals Ltd  
Kriya Therapeutics  
Kunming Yinnuo Medical Technology Co. Ltd.  
L2 Diagnostics LLC  
Landos Biopharma Inc  
Lannett Co Inc  
Larix Bioscience LLC  
Lexicon Pharmaceuticals Inc  
MannKind Corp  
Maruho Co Ltd  
Medytox Inc  
Mercia Pharma Inc  
Merck & Co Inc  
Metavant Sciences Ltd  
MidaSol Therapeutics LP  
Neovacs SA

NextCell Pharma AB  
Novartis AG  
Novo Nordisk AS  
OneVax LLC  
Op-T-Mune Inc  
Oramed Pharmaceuticals Inc  
Orgenesis Inc  
Orion BioScience Inc  
OSE Immunotherapeutics  
Pancryos AS  
Pandion Therapeutics Inc  
Paras Biopharmaceuticals Finland Oy  
Parvus Therapeutics Inc  
Pfizer Inc  
PharmaCyte Biotech Inc  
PoITREG Sp z o o  
Polus Inc  
Prometheon Pharma LLC  
Protomer Technologies Inc  
Provention Bio Inc  
Purzer Pharmaceutical Co Ltd  
RedHill Biopharma Ltd  
REGiMMUNE Corp  
Remd Biotherapeutics Inc  
reMYND NV  
Renova Therapeutics Inc  
Repertoire Immune Medicines  
Rezolute Inc  
Rubius Therapeutics Inc  
SAB Biotherapeutics Inc  
Sahane Biotech Inc  
Sanofi  
Sensulin LLC  
Seraxis Inc  
Serpina Pharma LLC  
Sihuan Pharmaceutical Holdings Group Ltd  
Sotio AS  
SQZ Biotechnologies Co  
Stelis Biopharma Pvt Ltd

Suntec Medical (Taiwan) Inc  
SymbioCellTech LLC  
Tetragenetics Inc  
TherapyX Inc  
Thermalin Inc  
Toleranzia AB  
Tolerion Inc  
Tolerx, Inc. (Inactive)  
Topas Therapeutics GmbH  
Transgene Biotek Ltd  
TwotoBiotech Ltd  
Unicyte AG  
Valin Technologies Ltd  
Ventria Bioscience  
Veralox Therapeutics Inc  
Vertex Pharmaceuticals Inc  
ViaCyte Inc  
ViCapsys Inc  
Virtici LLC  
vTv Therapeutics Inc  
XERIS Pharmaceuticals Inc  
XL-protein GmbH  
XOMA Corp  
Yichang Hec Changjiang Pharmaceutical Co Ltd  
Youngene Therapeutics Co Ltd  
Zealand Pharma AS  
Zhejiang Hisun Pharmaceutical Co Ltd

## I would like to order

Product name: Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/T288858333CEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T288858333CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970